Madrigal Pharmaceuticals (MDGL) Depreciation & Amortization (CF) (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 17 years of Depreciation & Amortization (CF) data on file, last reported at $386000.0 in Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) rose 1.85% year-over-year to $386000.0 in Q1 2026; TTM through Mar 2026 was $1.5 million, a 15.76% increase from a year earlier, with the FY2025 full-year figure at $1.5 million, up 37.41% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $386000.0, down from $392000.0 in the prior quarter.
• Over the last five years, Depreciation & Amortization (CF) for MDGL reached as high as $392000.0 in Q4 2025 and fell as low as $107000.0 in Q1 2022.
• Historically, Depreciation & Amortization (CF) has averaged $234235.3 across 5 years, with a median of $168000.0 in 2024.
• Across the five-year window, Depreciation & Amortization (CF) declined 5.31% in 2022 and surged 155.63% in 2024, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $129000.0 in 2022, then increased by 10.08% to $142000.0 in 2023, then jumped by 155.63% to $363000.0 in 2024, then increased by 7.99% to $392000.0 in 2025, then declined by 1.53% to $386000.0 in 2026.
• Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $386000.0 in Q1 2026, $392000.0 in Q4 2025, and $358000.0 in Q3 2025.